BioSpace News Archive

Advances in recombinant technology have enabled researchers to utilize the thrombolytic activity of tissue plasminogen activator (tPA) in synthetic products.

The 3D cell culture market is seeing a steady development because of the elements, as tremendous ventures by life science organizations for R&D, advancement of robotized enormous scale cell culture frameworks, and rising requirement for organ replacement.

Lyophilization has been popularly employed by the pharmaceuticals industry in parenteral product development.

Natural killer cells are generally big granular lymphocytes. These cells react quickly to any pathological problem.

The demand within the global stem cell banking market is growing on account of advancements in the field of regenerative medicine.

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), announced today their investment in Whitelab Genomics alongside French Venture Capital company, Omnes Capital, in a $10 Million Series A Round to advance their mission to accelerate the development of genomics medicines via technology powered by artificial intelligence (AI).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Gilead Foundation’s Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees.

The global systemic lupus erythematosus market is anticipated to grow at a healthy rate during the forecast period (2021 to 2031).

Rising need to develop technique that helps in minimizing the failure risks of drug discovery researches is projected to generate sizable sales prospects in the global ADME toxicology testing market during the forecast period of 2021 to 2031.

Duodenal ulcer occurs in the beginning of the small intestine also known as duodenum.